Inflammatory mass of an intrathecal catheter in patients receiving baclofen as a sole agent: A report of two cases and a review of the identification and treatment of the complication

Pain Medicine

Volumn 8, Issue 3, 2007, Pages 259-262

  Deer, Timothy R ^a,b   Raso, Louis J ^c   Garten, Tina G ^a  

^a Center for Pain Relief   (United States)

^b West Virginia University School of Medicine Charleston   (United States)

^c Three Palms Center   (United States)

Author keywords

Baclofen; Granuloma; Inflammatory Mass; Intrathecal; Spasticity

Indexed keywords

ANTICOAGULANT AGENT; BACLOFEN;

ADULT; AGED; ARTICLE; CASE REPORT; CATHETER COMPLICATION; CATHETER OCCLUSION; CATHETER REMOVAL; CEREBROVASCULAR ACCIDENT; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; FLACCID PARALYSIS; GRANULOMA; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; SPASTICITY; SYMPTOMATOLOGY;

ADULT; AGED; BACLOFEN; CATHETERIZATION; CEREBROVASCULAR ACCIDENT; FEMALE; GRANULOMA; HUMANS; INFLAMMATION; INFUSION PUMPS, IMPLANTABLE; INJECTIONS, SPINAL; MAGNETIC RESONANCE IMAGING; MALE; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; SPINE;

EID: 33947372916     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2006.00150.x     Document Type: Article

References (13)

1. Shetter AG, Hadley MN, Wilkinson E. Administration of intraspinal morphine sulfate for the treatment of intractable pain. J Neurosurg 1986; 18: 740-7.
2. Deer T, Chapple I, Classen A, et al. Intrathecal drug delivery for treatment of chronic low back pain: Report from the National Outcomes Registry for Low Back Pain. Pain Med 2004; 5: 6-13.
3. Smith T, Staats P, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: Impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002; 20: 4040-9.
4. North RB, Cutchis PN, Epstein JA, et al. Spinal cord compression complicating subarachnoid infusion of morphine: Case report and laboratory experience. Neurosurgery 1991; 29: 778-84.
5. Yaksh TL, Hassenbusch S, Burchiel K, et al. Inflammatory masses associated with intrathecal drug infusion: A review of preclinical evidence and human data. Pain Med 2002; 3: 300-12.
6. Bennett G, Deer T, Du Pen S, et al. Future directions in the management of pain by intraspinal drug delivery. J Pain Symptom Manage 2000; 20: S44-50.
7. Coffey R, Burchiel K. Inflammatory mass lesions associated with intrathecal drug infusion catheters: Report and observations on 41 patients. Neurosurgery 2002; 50: 78-86.
8. van Hilten BJ, van de Beek WJ, Hoff JI, et al. Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. N Engl J Med 2000; 343: 625-30.
9. Simpson RK Jr. Mechanisms of action of intrathecal medications. Neurosurg Clin N Am 2003; 14: 353-64.
10. Hassenbusch S, Burchiel K, Coffey RJ, et al. Management of intrathecal catheter-tip inflammatory masses: A consensus statement. Pain Med 2002; 3: 313-23.
11. Deer T. A prospective analysis of intrathecal granuloma in chronic pain patients: A review of the literature and report of a surveillance study. Pain Physician 2004; 7: 225-8.
12. McMillan M, Doud T, Nugent W. Catheter associated masses in patients receiving intrathecal analgesictherapy. Anesth Analg 2003; 96: 186-90.
13. Follett KA, Naumann CP. A prospective study of catheter-related complications of intrathecal drug delivery systems. J Pain Symptom Manage 2000; 19: 209-15.